Zai Lab (ZLAB) said Monday that a phase 3 clinical trial evaluating first-line bemarituzumab plus chemotherapy for the treatment of gastric cancer met its primary endpoint of overall survival at an interim analysis.

The biopharmaceutical company said the treatment combination demonstrated a "statistically significant and clinically meaningful" improvement in overall survival compared with placebo plus chemotherapy.

Zai Lab also said that a phase 3 trial of bemarituzumab plus chemotherapy and nivolumab is ongoing and that data readout is expected in H2.

Shares of Zai Lab were up 2.1% in recent early trading.

Price: 35.46, Change: +0.71, Percent Change: +2.06